UB Therapeutics

UB Therapeutics Overview

UB Therapeutics is a biotechnology company developing a novel therapy for the treatment of multiple myeloma. The company’s compound is a cyclic peptide with potential anticancer therapeutic activity. The cyclic peptides block the action of deubiquitinases and the proteasome, induce apoptosis in vitro, and attenuate tumor growth in vivo. These cyclic peptides show in vitro and in vivo activity comparable to a small molecule proteasome inhibitor and similarly induce apoptosis in cancer cells. Whereas the immediate target of small molecules proteasome inhibitors such as bortezomib is the chymotrypsin-like β5 catalytic subunit of the proteasome, the cyclic peptides impair the recognition and subsequent proteasomal degradation of ubiquitinylated proteins.

Cumulative Funding Raised Over Time ($)

Latest News

Aug 2, 2023 · www.calcalistech.com

growth-positive

This company is fighting against cancer drug resistance | CTech

UB-Therapeutics, a company focused on addressing drug resistance in multiple myeloma cancer, has raised nearly $500,000. The companys approach involves inhibiting proteasome activity by binding to ubiquitin, a novel approach that hasnt been explored extensively in the context of multiple myeloma. The companys product doesnt exist yet, but the founders expect to enter the first-in-human trial within three years. The investment will be used for the development of a stable and effective formulation for their cyclic peptide, for the planning of their regulatory roadmap, and for R&D.

Investment

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

Wadi el-Haj St 13, Nazareth, Israel

Photos & Videos

No files yet

UB Therapeutics Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info